Found: 4
Select item for more details and to access through your institution.
A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
- Published in:
- Cancers, 2020, v. 12, n. 6, p. 1425, doi. 10.3390/cancers12061425
- By:
- Publication type:
- Article
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 409, doi. 10.1007/s10637-012-9904-9
- By:
- Publication type:
- Article
A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 2, p. 399, doi. 10.1007/s10637-012-9890-y
- By:
- Publication type:
- Article
Phase I study of afatinib combined with nintedanib in patients with advanced solid tumours.
- Published in:
- 2015
- By:
- Publication type:
- journal article